Issued Patents All Time
Showing 1–25 of 26 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12286487 | Antibody compounds with reactive arginine and related antibody drug conjugates | Dobeen Hwang, Napon Nilchan | 2025-04-29 |
| 12281167 | Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs) | Donald L. Siegel, Vijay Bhoj, Rebecca Goydel | 2025-04-22 |
| 11970525 | Treatment of cancer using GFR alpha-4 chimeric antigen receptor | Donald L. Siegel, Michael C. Milone, Vijay Bhoj | 2024-04-30 |
| 11834501 | ROR2 antibody compositions and related methods | Haiyong Peng, Xiuling Li | 2023-12-05 |
| 11802159 | Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs) | Donald L. Siegel, Vijay Bhoj, Rebecca Goydel | 2023-10-31 |
| 11384139 | Antibody targeting cell surface deposited complement protein C3d and use thereof | Adrian Wiestner, Martin W. Skarzynski, Margaret LINDORFER, Ronald P. Taylor, Berengere Vire | 2022-07-12 |
| 11242388 | ROR1 antibody compositions and related methods | Haiyong Peng, Roger Beerli, Lorenz Waldmeier, Ulf Grawunder | 2022-02-08 |
| 11197934 | Dual variable domain immunoconjugates and uses thereof | Alex Nanna, William R. Roush | 2021-12-14 |
| 11078235 | Cyclic peptide conjugates and methods of use | Lori Hazlehurst, Xiuling Li, Mark McLaughlin | 2021-08-03 |
| 11078273 | ROR2 antibody compositions and related methods | Haiyong Peng, Xiuling Li | 2021-08-03 |
| 10851149 | Treatment of cancer using GFR α-4 chimeric antigen receptor | Donald L. Siegel, Michael C. Milone, Vijay Bhoj | 2020-12-01 |
| 10618959 | ROR1 antibody compositions and related methods | Haiyong Peng, Roger Beerli, Lorenz Waldmeier, Ulf Grawunder | 2020-04-14 |
| 10035848 | Antibody targeting cell surface deposited complement protein C3d and use thereof | Adrian Wiestner, Martin W. Skarzynski, Margaret LINDORFER, Ronald P. Taylor, Berengere Vire | 2018-07-31 |
| 10011635 | Cyclic peptide conjugates and methods of use | Lori Hazlehurst, Xiuling Li, Mark McLaughlin | 2018-07-03 |
| 9758586 | Chimeric rabbit/human ROR1 antibodies | Jiahui Yang | 2017-09-12 |
| 9316646 | Anti-human ROR1 antibodies | Sivasubramanian Baskar | 2016-04-19 |
| 9273136 | Fully human anti-human NKG2D monoclonal antibodies | Ka Y. KWONG | 2016-03-01 |
| 9163258 | Method for the treatment of obesity | Stanley R. Riddell, Michael HUDECEK | 2015-10-20 |
| 8916159 | Selenocysteine mediated hybrid antibody molecules | Thomas Hofer, Terrence R. Burke, Jr., Joshua D. Thomas | 2014-12-23 |
| 8877199 | B cell surface reactive antibodies | Sivasubramanian Baskar, Michael R. Bishop, Ivan Samija, Jessica M. Suschak | 2014-11-04 |
| 8252902 | Antibody targeting compounds | Carlos F. Barbas, III, Subhash C. Sinha, Richard A. Lerner | 2012-08-28 |
| 7087409 | Humanization of murine antibody | Carlos F. Barbas, III | 2006-08-08 |
| 6677435 | Prodrug activation using catalytic antibodies | Carlos F. Barbas, III, Doron Shabat, Benjamin List, Richard A. Lerner | 2004-01-13 |
| 6346249 | Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products | Carlos F. Barbas, III, Gerd Ritter, Sydney Welt, Lloyd J. Old | 2002-02-12 |
| 6342587 | A33 antigen specific immunoglobulin products and uses thereof | Carlos F. Barbas, III, Gerd Ritter, Sydney Welt, Lloyd J. Old | 2002-01-29 |